186 related articles for article (PubMed ID: 35254695)
1. Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist.
Nephew LD; Wang Y; Mohamed K; Nichols D; Rawl SM; Orman E; Desai AP; Patidar KR; Ghabril M; Chalasani N; Kasting ML
J Viral Hepat; 2022 May; 29(5):366-374. PubMed ID: 35254695
[TBL] [Abstract][Full Text] [Related]
2. Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020.
Thompson WW; Symum H; Sandul A; ; Gupta N; Patel P; Nelson N; Mermin J; Wester C
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(32):1011-1017. PubMed ID: 35951484
[TBL] [Abstract][Full Text] [Related]
3. Changes in Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programs.
Davey S; Costello K; Russo M; Davies S; Lalani HS; Kesselheim AS; Rome BN
JAMA Health Forum; 2024 Apr; 5(4):e240302. PubMed ID: 38578628
[TBL] [Abstract][Full Text] [Related]
4. Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis.
Herink MC; Geddes J; Vo K; Zaman A; Hartung DM
J Manag Care Spec Pharm; 2021 Jul; 27(7):856-864. PubMed ID: 34185560
[No Abstract] [Full Text] [Related]
5. Hepatitis C Treatment Initiation Among US Medicaid Enrollees.
Kapadia SN; Zhang H; Gonzalez CJ; Sen B; Franco R; Hutchings K; Wethington E; Talal A; Lloyd A; Dharia A; Wells M; Bao Y; Shapiro MF
JAMA Netw Open; 2023 Aug; 6(8):e2327326. PubMed ID: 37540513
[TBL] [Abstract][Full Text] [Related]
6. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
J Clin Gastroenterol; 2018 Aug; 52(7):641-647. PubMed ID: 28590325
[TBL] [Abstract][Full Text] [Related]
7. Disparities in Access to Hepatitis C Treatment Among Arizona Medicaid Beneficiaries With Chronic Hepatitis C.
Jiang X; Song HJ; Chang CY; Wilson D; Guo J; Lo-Ciganic WH; Park H
Med Care; 2023 Feb; 61(2):81-86. PubMed ID: 36453625
[TBL] [Abstract][Full Text] [Related]
8. Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.
Wong RJ; Jain MK; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Thamer M
Am J Gastroenterol; 2018 Sep; 113(9):1329-1338. PubMed ID: 29523864
[TBL] [Abstract][Full Text] [Related]
9. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors.
Bova S; Cameron A; Durand C; Katzianer J; LeGrand M; Boyer L; Glorioso J; Toman LP
Am J Health Syst Pharm; 2022 Jan; 79(3):173-178. PubMed ID: 33987658
[TBL] [Abstract][Full Text] [Related]
10. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C.
Park H; Song HJ; Jiang X; Henry L; Cook RL; Nelson DR
Hepatol Commun; 2021 Feb; 5(2):203-216. PubMed ID: 33553969
[TBL] [Abstract][Full Text] [Related]
11. Medicaid Hepatitis C Virus Treatment Policies: Impact on Testing and Treatment in the Commercially Insured.
Epstein RL; Wang J; White LF; Kapadia SN; Morgan JR; Bao Y; Linas BP
Am J Prev Med; 2022 Sep; 63(3):e87-e98. PubMed ID: 35725599
[TBL] [Abstract][Full Text] [Related]
12. Medicaid Expansion Association With End-Stage Liver Disease Mortality Depends on Leniency of Medicaid Hepatitis C Virus Coverage.
Wahid NA; Lee J; Kaplan A; Fortune BE; Safford MM; Brown RS; Rosenblatt R
Liver Transpl; 2021 Dec; 27(12):1723-1732. PubMed ID: 34118120
[TBL] [Abstract][Full Text] [Related]
13. Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.
Marcus JL; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Lam JO; Pauly MP; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ
Public Health Rep; 2018; 133(4):452-460. PubMed ID: 29750893
[TBL] [Abstract][Full Text] [Related]
14. Temporal Trends in Hepatitis C-Related Hospitalizations, United States, 2000-2019.
Hofmeister MG; Zhong Y; Moorman AC; Samuel CR; Teshale EH; Spradling PR
Clin Infect Dis; 2023 Dec; 77(12):1668-1675. PubMed ID: 37463305
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.
Nguyen VH; Kam L; Yeo YH; Huang DQ; Henry L; Cheung R; Nguyen MH
JAMA Netw Open; 2022 Dec; 5(12):e2245424. PubMed ID: 36477481
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C in Black Individuals in the US: A Review.
Falade-Nwulia O; Kelly SM; Amanor-Boadu S; Nnodum BN; Lim JK; Sulkowski M
JAMA; 2023 Dec; 330(22):2200-2208. PubMed ID: 37943553
[TBL] [Abstract][Full Text] [Related]
17. Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study.
Clements KM; Clark RE; Lavitas P; Kunte P; Graham CS; O'Connell E; Lenz K; Jeffrey P
J Manag Care Spec Pharm; 2016 Jun; 22(6):714-722b. PubMed ID: 27231798
[TBL] [Abstract][Full Text] [Related]
18. The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.
Chu C; Gomes T; Antoniou T; Wong WWL; Janjua N; Guertin JR; Schwartz KL; Feld J; Kwong J; Tadrous M
PLoS One; 2023; 18(8):e0284914. PubMed ID: 37552677
[TBL] [Abstract][Full Text] [Related]
19. Sustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment Access.
Martin MT; Waring N; Forrest J; Nazari JL; Abdelaziz AI; Lee TA
Public Health Rep; 2023; 138(3):467-474. PubMed ID: 35674245
[TBL] [Abstract][Full Text] [Related]
20. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?
Du P; Wang X; Kong L; Jung J
Telemed J E Health; 2021 May; 27(5):488-494. PubMed ID: 32882154
[No Abstract] [Full Text] [Related]
[Next] [New Search]